Novantron (Mitoxantrone Hydrochloride)

Mitoxantrone hydrochloride intercalates into DNA and stabilizes the topoisomerase II‑DNA complex, preventing the re‑ligation of DNA strands. This results in persistent double‑strand breaks, leading to apoptosis of rapidly dividing cells such as cancerous lymphocytes and myeloid precursors.

The dose and schedule of Novantron are individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and prior treatment history. No fixed regimen is provided publicly; the prescriber sets the appropriate regimen.

Novantron is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided in pregnant women unless the potential therapeutic benefit justifies the risk. Breastfeeding is not recommended because the drug can be excreted in milk and may harm the infant.

To order Novantron, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Novantron belongs to the anthracenedione class, offering a distinct mechanism of DNA intercalation and topoisomerase II inhibition compared with alkylating agents or taxanes. Its efficacy in certain leukemias and solid tumours is comparable to other cytotoxics, but it carries a unique risk profile, especially for cardiotoxicity and secondary malignancies.

Novantron should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If temporary storage at controlled room temperature is unavoidable, limit exposure to less than 24 hours.

Novantron is supplied as a sterile injection solution and is administered intravenously, intraperitoneally, or intrapleurally by a qualified healthcare professional. The infusion rate and volume are determined by the prescriber and nursing staff according to the treatment protocol and patient tolerance.

The most serious adverse events include dose‑related cardiotoxicity, secondary acute myeloid leukemia, severe myelosuppression leading to infections or bleeding, and rare pulmonary toxicity. Patients should be monitored closely with cardiac imaging, blood counts, and clinical assessment throughout therapy.

Novantron is contraindicated in patients with known hypersensitivity to mitoxantrone or any formulation component, in those with uncontrolled cardiac disease, and in pregnant women unless no alternative exists. Caution is also advised for individuals with severe hepatic or renal impairment.